TT-OAD2

Cat. No.:	HY-129658A
CAS No.:	2382719-60-8
Molecular Formula:	$C_{50}H_{49}Cl_4N_3O_6$
Molecular Weight:	929.75
Target:	GCGR
Pathway:	GPCR/G Protein
Storage:	4°C, sealed storage, away from moisture and light * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)



BIOLOGICAL ACTIVITY

Description	TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC_{50} of 5 nM. TT-OAD2 has the potential for diabetes treatment[1][2].
IC_{50} & Target	EC50: 5 nM (GLP-1 receptor)[2]
In Vitro	TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male human GLP-1 receptor knock-in and knockout mice (6-11 months of age) with intravenous glucose tolerance tests[1]
Dosage:	3 mg/kg
Administration:	Intravenous injection (Single dose)
Result:	Induced plasma insulin.

REFERENCES

[1]. Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436.

[2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA